Synapse - CTCR Scholars

Results (1639)

Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)

Meeting Abstract

Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
Blood (2021)

Fulltext@MSK | Save

Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience

Meeting Abstract

Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
Blood (2021)

Fulltext@MSK | Save

Predictors of central nervous system (CNS) involvement in North American adult T-cell leukemia lymphoma (ATLL) and their survival pattern

Meeting Abstract

Patel, R.; Rahman, S.; Shah, N.; Thakkar, A.; Acuna-Villaorduna, A.; Shah, U. A.; Herrera, D. A.; De Castro, A.; Mustafa, J.; Khatun, F.; more...
Blood (2021)

Fulltext@MSK | Save

First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL

Meeting Abstract

Park, J. H.; Winer, E. S.; Huntington, S. F.; von Keudell, G.; Vemuri, S.; Shukla, M.; Kinoshita, J. C.; Falco, V.; Gore, S. D.; Stone, R. M.; more...
Blood (2021)

Fulltext@MSK | Save

CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study

Meeting Abstract

Patel, K.; Zonder, J. A.; Sano, D.; Maris, M.; Lesokhin, A.; von Keudell, G.; Lai, C.; Ramchandren, R.; Catalano, T.; Lin, G. H. Y.; more...
Blood (2021)

Fulltext@MSK | Save

Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplantation (SCT)

Meeting Abstract

Mishra, A.; Tamari, R.; DeZern, A. E.; Byrne, M. T.; Gooptu, M.; Chen, Y. B.; Deeg, H. J.; Gallacher, P.; Wennborg, A.; Hickman, D. K.; more...
Blood (2021)

Fulltext@MSK | Save

Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)

Meeting Abstract

Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
Blood (2021)

Fulltext@MSK | Save

Interim results of a pilot, prospective, randomized, double-blinded, vehicle- and comparator-controlled trial on safety and efficacy of a topical inhibitor of janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non- sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease

Meeting Abstract

Markova, A.; Pan, A.; Dusza, S.; Chowdhury, A.; Kukoyi, O.; Perales, M. A.; Lacouture, M.; Prockop, S.; Ponce, D. M.
Blood (2021)

Fulltext@MSK | Save

Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma

Meeting Abstract

Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
Blood (2021)

Fulltext@MSK | Save

Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy

Meeting Abstract

Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
Blood (2021)

Fulltext@MSK | Save